Takeda Oncology
Charlotte Darby is a Senior Scientist in Computational Oncology at Takeda Oncology since March 2021, leading various projects focused on translational strategy and data analysis while building bioinformatics and AI/ML infrastructure. Previously, Charlotte served as a Senior Computational Biologist at the New York Genome Center, enhancing the Seurat single-cell analysis R package and deploying the Azimuth Shiny application. Additional experience includes roles as a Summer Research Intern at 10x Genomics, a Graduate Research Intern at IBM Almaden Research Center, and various teaching positions at The Johns Hopkins University and Carnegie Mellon University. Charlotte holds a PhD in Computer Science from The Johns Hopkins University, an MS in Computational Biology from Carnegie Mellon University, and a BS in the same field from Carnegie Mellon.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.